Meet the pharma company with a build-as-you go approach

Amarin Corporation is the pharmaceutical company behind Vazkepa, a drug for?cardiovascular disease. The way Amarin operates is rather different to typical biopharma companies – by adopting a very?agile business model, it has been able to adapt to changing circumstances with a?"build-as-you-go" approach, enabling it to establish a commercial presence in multiple European countries in record time.

We spoke to Laurent Abuaf, Amarin's SVP and President for Europe, about its country-by country strategy. Read more.

When it comes to ensuring a merger and acquisition (M&A) is successful, regulatory compliance, an integration strategy and having the right team in place are vital. Lynne Byers, Global Managing Director for Pharmaceuticals and Dietary Supplements Consulting at NSF, discusses why scientific due diligence is essential in pharma M&As. Read more.

Single-use systems are becoming increasingly important in manufacturing and the supply chain. Ken Wong, Sanofi’s Head of Procurement for Asia, tells us about the benefits and challenges of single-use, and why they might actually be more sustainable than fixed use equipment. Read more.

Ahead of?Pharma IQ's OPEX Pharma conference in February 2023, we look back at this interview with Nadine De Decker, Director of Strategic Business Improvement at Johnson & Johnson, where she shares her insights on why change management is necessary within the pharmaceutical industry and how to ensure change is implemented successfully.?Read more.